Investors Face October 13 Deadline in Aardvark Therapeutics Lawsuit

The litigation, spearheaded by the Rosen Law Firm, focuses on statements made during the company’s February 2025 initial public offering and the subsequent months. According to the complaint, Aardvark Therapeutics allegedly failed to disclose that ARD-101 presented safety concerns that undermined its clinical and regulatory viability. Plaintiffs claim these omissions resulted in artificially inflated stock prices and subsequent financial damages for shareholders when the true details emerged.

Investors wishing to participate in the litigation are not required to serve as lead plaintiff to share in any potential recovery. However, those interested in directing the case must file a motion with the court by the October 13 deadline. The Rosen Law Firm notes that the class has not yet been certified, meaning investors remain unrepresented unless they retain counsel of their choice or join the existing action.